The Affiliated Hospital of Hangzhou Normal University

Hangzhou 310015

2 studies enrolling now · 7 studies all time

What they study most

Atrial Fibrillation, Hypertension, Portal, Ischemic Stroke; Ischemic Attack, Transient, Liver Diseases, Liver Fibrosis, Metabolic Dysfunction Associated Steatohepatitis, Metabolic Dysfunction Associated Steatohepatitis (MASH), Secondary Prevention, Stroke

Studies at this site

• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — Recruiting now
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — Recruiting now
• A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE — Running, not enrolling
• A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) — Stopped early
• A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) — Stopped early
• GLORIA-AF Registry Program - Second and Third Phases — Completed
• Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) — Completed